CRISPR Therapeutics (CRSP) today announced that members of its management team will participate in the 41st Annual Growth Conference on August 12, 2021. The stock traded at $124.61 on yesterday’s trading session marking a 2.63% jump. As of the pre-market session, the stock is up 1.32% in the market. The market capitalization for CRISPR Therapeutics equals $9.49 billion.
CRISPR Therapeutics AG is a company that edits genes and develops drugs and treatments for many severe diseases using its proprietary technology platform. Through its collaborations with leading companies, it has established a robust platform to accelerate its efforts.

The company’s lead product is CTX001, which is an ex vivo CRISPR gene-editing therapy that’s designed to produce high levels of blood plasma in patients with severe sickle cell disease. It also develops other allogeneic CAR T cell programs. CRISPR Therapeutics AG is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of serious diseases. It has collaborations with various pharmaceutical companies, including Pfizer, Eli Lilly, and Vertex Pharmaceuticals Incorporated.

Ezoicreport this ad

Source link